These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21038133)

  • 1. Evaluation of the functional parameters in scleroderma cases with pulmonary involvement.
    Celebi Sözener Z; Karabıyıkoğlu G; Düzgün N
    Tuberk Toraks; 2010; 58(3):235-41. PubMed ID: 21038133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
    Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive diagnostic and functional evaluation of cardiac and pulmonary involvement in systemic sclerosis.
    Sergiacomi G; De Nardo D; Capria A; Manenti G; Fabiano S; Borzi M; De Sanctis G; Konda D; Sperandio M; Schillaci O; Masala S; Simonetti G; Fontana L
    In Vivo; 2004; 18(2):229-35. PubMed ID: 15113051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease.
    Wilsher M; Good N; Hopkins R; Young P; Milne D; Gibson A; Suppiah R; Ly J; Doughty R; Dalbeth N
    Respirology; 2012 May; 17(4):647-52. PubMed ID: 22256786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients.
    Villalba WO; Sampaio-Barros PD; Pereira MC; Cerqueira EM; Leme CA; Marques-Neto JF; Paschoal IA
    Chest; 2007 Jan; 131(1):217-22. PubMed ID: 17218579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we predict the severity of pulmonary hypertension in patients with scleroderma?
    Acosta Colmán MI; Avila Pedretti G; Acosta ME; Simeón Aznar CP; Fonollosa Plá V; Villardel Torrés M
    Reumatol Clin; 2012; 8(5):259-62. PubMed ID: 22658662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pulmonary involvement in sclerodermia].
    Paone G; Di Michele L; Mattia P; Tonnarini R; Lucifora V; Fiorucci F
    Minerva Med; 1994 Jun; 85(6):293-300. PubMed ID: 8084431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis.
    Beretta L; Santaniello A; Lemos A; Masciocchi M; Scorza R
    Rheumatology (Oxford); 2007 Feb; 46(2):296-301. PubMed ID: 16877463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessments of pulmonary involvement in patients with systemic sclerosis.
    Gohari Moghadam K; Gharibdoost F; Parastandechehr G; Salehian P
    Arch Iran Med; 2011 Jan; 14(1):22-6. PubMed ID: 21194257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
    Dimopoulou I; Galani H; Dafni U; Samakovii A; Roussos C; Dimopoulos MA
    Cancer; 2002 Jan; 94(2):452-8. PubMed ID: 11900231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
    Garin MC; Highland KB; Silver RM; Strange C
    J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.
    Plastiras SC; Karadimitrakis SP; Ziakas PD; Vlachoyiannopoulos PG; Moutsopoulos HM; Tzelepis GE
    Arthritis Rheum; 2006 Aug; 55(4):598-602. PubMed ID: 16874782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
    Steen V; Medsger TA
    Arthritis Rheum; 2003 Feb; 48(2):516-22. PubMed ID: 12571862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Longitudinal study of parameters of respiratory function tests and blood gas analysis in patients with progressive systemic scleroderma].
    Georgiev O; Shoshkov P; Rashkov R
    Vutr Boles; 2001; 33(2-3):37-40. PubMed ID: 12001574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary functions in children with progressive systemic sclerosis.
    Garty BZ; Athreya BH; Wilmott R; Scarpa N; Doughty R; Douglas SD
    Pediatrics; 1991 Dec; 88(6):1161-7. PubMed ID: 1956732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum interleukin-6 in systemic sclerosis and its correlation with disease parameters and cardiopulmonary involvement.
    Abdel-Magied RA; Kamel SR; Said AF; Ali HM; Abdel Gawad EA; Moussa MM
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Dec; 33(4):321-330. PubMed ID: 28079844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement.
    de Oliveira NC; dos Santos Sabbag LM; Ueno LM; de Souza RB; Borges CL; de Sá Pinto AL; Lima FR
    Scand J Rheumatol; 2007; 36(6):458-61. PubMed ID: 18092268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cross-sectional and longitudinal association of the BODE index with quality of life in patients with chronic obstructive pulmonary disease.
    Lin YX; Xu WN; Liang LR; Pang BS; Nie XH; Zhang J; Wang H; Liu YX; Wang DQ; Xu ZY; Wang HW; Zhang HS; He ZY; Yang T; Wang C
    Chin Med J (Engl); 2009 Dec; 122(24):2939-44. PubMed ID: 20137478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.